Publications by authors named "Jingliao Zhang"

Objectives: To investigate the genomic characteristics and prognostic factors of juvenile myelomonocytic leukemia (JMML) with mutations.

Methods: A retrospective analysis was conducted on the clinical data of JMML children with mutations treated at the Hematology Hospital of Chinese Academy of Medical Sciences, from January 2008 to November 2022.

Results: A total of 34 children were included, with 17 cases (50%) having isolated mutations, 9 cases (27%) having isolated mutations, and 8 cases (24%) having compound mutations.

View Article and Find Full Text PDF

Background: T-cell malignancies are highly aggressive hematological tumors with limited effective treatment options. CAR-NK cell therapy targeting CD7 has emerged as a promising approach for treating T-cell malignancies. However, conventional CAR-NK cell therapy faces the challenges of cell fratricide due to CD7 expression on both malignant cells and normal NK cells.

View Article and Find Full Text PDF

Paediatric relapse/refractory T-cell acute lymphoblastic leukaemia (T-ALL) is notoriously difficult to treat. This group of heavily pre-treated patients needs effective agents that can rapidly control the disease while not having significant toxicity. Homoharringtonine (HHT) has been widely used in children with acute myeloid leukaemia, but there is little information on T-ALL.

View Article and Find Full Text PDF

Pediatric acute myeloid leukemia (pAML) is a clonal disease with recurrent genetic alterations that affect epigenetic states. However, the implications of epigenetic dysregulation in disease progression remain unclear. Here, we interrogated single-cell and clonal level chromatin accessibility of bone marrow samples from 28 patients with pAML representing multiple subtypes using mitochondrial single-cell assay for transposase-accessible chromatin with sequencing, which revealed distinct differentiation hierarchies and abnormal chromatin accessibility in a subtype-specific manner.

View Article and Find Full Text PDF

Objective: RS4;11 cell line was used to establish BCL-2 inhibitor-resistant cell lines of B-cell acute lymphoblastic leukemia (B-ALL) and explore the possible mechanisms of drug resistance.

Methods: RS4;11 cell line was continuously induced and cultured by low and ascending concentrations of BCL-2 inhibitors navitoclax and venetoclax to construct navitoclax-resistant cell line RS4;11/Nav and venetoclax-resistant cell line RS4;11/Ven. The cell viability was detected by MTT assay, and the cell apoptosis was detected by flow cytometry.

View Article and Find Full Text PDF

Relapse and treatment resistance pose significant challenges in the management of pediatric B cell acute lymphoblastic leukemia (B-ALL) and acute myeloid leukemia (AML). The efficacy of immunotherapy in leukemia remains limited due to factors such as the immunosuppressive tumor microenvironment (TME) and lack of suitable immunotherapeutic targets. Thus, an in-depth characterization of the TME in pediatric leukemia is warranted to improve the efficacy of immunotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Juvenile myelomonocytic leukemia (JMML) is a complex blood disorder found mainly in infants and young children, where both overproduction and abnormal development of blood cells occur.
  • Current methods for predicting patient outcomes in JMML are inadequate, leading researchers to seek new prognostic indicators like red cell distribution width (RDW), which reflects the size variability of red blood cells.
  • A study found that a higher RDW (over 17.35%) at diagnosis significantly correlates with worse survival rates, suggesting RDW could be an affordable and insightful biomarker for predicting outcomes in JMML patients.*
View Article and Find Full Text PDF
Article Synopsis
  • Researchers studied how leukemia develops in B cells and its impact on drug sensitivity.
  • They found that different developmental states of B cell acute lymphoblastic leukemia (B-ALL) significantly affect how sensitive the leukemia is to asparaginase, a chemotherapy drug.
  • By targeting a specific protein (BCL2) in resistant leukemia cells, they showed that combining it with asparaginase improves treatment effectiveness, highlighting potential strategies for personalized therapy in B-ALL and possibly other cancers.
View Article and Find Full Text PDF
Article Synopsis
  • * Two main evolutionary patterns identified in T-ALL are "clonal shift," where new clones emerge, and "clonal drift," where existing clones continue to evolve.
  • * The RNA-binding protein MSI2 was found to be significantly upregulated in persistent TCR clonotypes at relapse, suggesting it plays a role in tumor growth and chemotherapy resistance, making it a potential new target for treatment.
View Article and Find Full Text PDF
Article Synopsis
  • - A research study aimed to create a better prediction model for long-term outcomes in children with severe aplastic anemia (SAA) after receiving immunosuppressive therapy (IST) using data from 203 newly diagnosed patients.
  • - The study employed machine-learning techniques to identify important health indicators, such as blood cell counts and inflammatory markers, that strongly correlate with therapy outcomes.
  • - Findings suggest that this new model could help healthcare providers more quickly assess treatment effectiveness and potentially lower the costs and duration of the treatment for SAA.
View Article and Find Full Text PDF
Article Synopsis
  • * A review of olverembatinib, a third-generation ABL inhibitor, showed promising efficacy and safety in 7 children with relapsed Ph ALL or ABL class fusion, particularly those who had intolerance to previous treatments like dasatinib.
  • * Among the patients treated, 4 out of 5 evaluable children achieved complete remission with minimal disease detection, and the side effects observed were generally mild, indicating that olverembatinib may be a viable treatment option for this population.
View Article and Find Full Text PDF

Acquired aplastic anemia (AA) is recognized as an immune-mediated disorder resulting from active destruction of hematopoietic cells in bone marrow (BM) by effector T lymphocytes. Bulk genomic landscape analysis and transcriptomic profiling have contributed to a better understanding of the recurrent cytogenetic abnormalities and immunologic cues associated with the onset of hematopoietic destruction. However, the functional mechanistic determinants underlying the complexity of heterogeneous T lymphocyte populations as well as their correlation with clinical outcomes remain to be elucidated.

View Article and Find Full Text PDF
Article Synopsis
  • - Juvenile myelomonocytic leukemia (JMML) is a serious type of blood cancer in children, and patients often can't undergo critical treatment like stem cell transplants due to their fragile health at diagnosis.
  • - This study examined the effects of decitabine-based therapy on 10 JMML patients, finding that after three treatment cycles, 71.4% showed improvement, alongside significant reductions in white blood cell and monocyte counts.
  • - After one year, the study reported an 80% progression-free survival rate, suggesting decitabine therapy effectively helps reduce cancer burden and enhance patient condition prior to transplant.
View Article and Find Full Text PDF
Article Synopsis
  • FLT3 is a promising target for treating acute lymphoblastic leukemia (ALL), but how it's activated in this disease isn't fully understood.
  • Researchers found that ALL patients with ZNF384 gene rearrangements consistently over-express FLT3, linked to a specific enhancer element that activates FLT3 only in these cases.
  • Reducing ZNF384 levels decreases FLT3 activation and makes ALL cells less responsive to the FLT3 inhibitor gilteritinib, which has shown effective anti-leukemia effects in models of ZNF384-rearranged ALL.
View Article and Find Full Text PDF
Article Synopsis
  • * They show superior performance compared to traditional drugs, effectively tackling difficult-to-target cancer proteins while showing better selectivity and fewer side effects.
  • * Despite their potential, PROTACs face challenges in design, testing, and practical use, but ongoing research aims to optimize their application in clinical settings for patients with hematologic malignancies.
View Article and Find Full Text PDF

The prognosis of patients with T-cell acute lymphoblastic leukemia (T-ALL) has been largely lacked behind than that of patients with B-cell ALL, especially in refractory or relapsed cases. Here, we describe a 4.7-year-old male child with TCF-SPI1-postitve T-ALL who developed refractoriness disease after a seven drugs-conventional therapy.

View Article and Find Full Text PDF
Article Synopsis
  • Minimal residual disease (MRD) after chemotherapy is a key indicator for predicting outcomes in cancers, but understanding its resistance mechanisms is challenging due to the rarity and variety of these residual cells.
  • Researchers conducted a study analyzing over 161,000 single-cell transcriptomes to examine changes in B-cell acute lymphoblastic leukaemia (B-ALL) from diagnosis to relapse and residual states.
  • They found that relapse leukaemic cells often became less differentiated, and residual cells activated a hypoxia pathway, which when inhibited, made the leukaemic cells more responsive to chemotherapy, offering new treatment possibilities for B-ALL.
View Article and Find Full Text PDF
Article Synopsis
  • - The study analyzed clinical characteristics and prognosis factors in 205 children with severe aplastic anemia (SAA) treated from 2008 to 2018, focusing on their response to immunosuppressive therapy (IST).
  • - Results showed that by 12 months post-treatment, over 73% of patients had a positive response, and the 5-year overall survival rate was impressive at 93.1%.
  • - While the mode of delivery (spontaneous vs. cesarean) seemed to have an impact on short-term survival rates, it was not significant in the long term, and a recent history of home or school decoration was linked to better short-term responses to treatment.
View Article and Find Full Text PDF
Article Synopsis
  • - Dasatinib, a drug used to treat CBF-AML, was tested in a study with 20 children to assess its pharmacokinetics and safety when combined with standard chemotherapy.
  • - Blood samples were taken to analyze dasatinib concentrations, revealing that the drug’s effectiveness (measured by AUC) in children was comparable to that in adults, with some adverse effects mostly being mild (grade 1/2).
  • - The study found high rates of complete remission (95%) and molecular response (75.5%) in pediatric patients, indicating that dasatinib is well-tolerated and effective for treating CBF-AML in children.
View Article and Find Full Text PDF
Article Synopsis
  • T-cell acute lymphoblastic leukemia (T-ALL) is a serious blood cancer that shows varying drug responses, with about 44% of children and 17% of adults responding well to the drug dasatinib.
  • Research found that the activation of a specific signaling pathway (preTCR-LCK) is key to why some T-ALL cases are sensitive to dasatinib, while other cases are resistant to a different drug called venetoclax.
  • The study highlights that the developmental stage of T-cells in leukemia influences which signaling pathways are active, suggesting potential for developing targeted therapies based on a patient's specific leukemia characteristics.
View Article and Find Full Text PDF

The acute inflammatory stimulation occurring after a bone fracture regulates the repair and healing of local bone injury; however, under certain conditions, pyroptosis may occur in osteoblasts, which affects osteoblast proliferation and differentiation, thereby affecting the growth, development and morphological changes of bone tissue. The aim of the present study was to examine the effect of the pyroptosis inhibitor necrosulfonamide (NSA) on the proliferation and differentiation of osteoblasts and elucidate the underlying mechanism. The results revealed that NSA reversed the effects of ATP/lipopolysaccharide (LPS) on cell viability and pyroptosis, and on the mRNA and protein expression of pyroptosis-related genes.

View Article and Find Full Text PDF
Article Synopsis
  • Actin is crucial for various cellular functions, including cell migration and maintaining shape, and this study examines how its polymerization affects the differentiation of human adipose-derived stem cells (hASCs) into bone-forming cells.
  • The research involved treating hASCs with different concentrations of jasplakinolide (JAS) to enhance actin polymerization, measuring impacts on cell proliferation, migration, and focal adhesion protein levels, finding that optimal JAS concentration improved these factors.
  • Results showed increased osteogenic differentiation of hASCs with varying JAS concentrations, indicating a concentration-dependent role of actin polymerization in this process and highlighting potential mechanisms for bone tissue engineering.
View Article and Find Full Text PDF

This study retrospectively analyzed the clinical outcome of 172 children with newly diagnosed severe aplastic anemia (SAA) between January 2008 and April 2018, who received rabbit antithymocyte globulin (ATG) and cyclosporine (CsA) as first-line treatment. The median age at diagnosis was 5 years (range, 1-14). The overall response rates were 22.

View Article and Find Full Text PDF